Albany Molecular Research, Inc. Renews Relationship with Eli Lilly and Company
Advertisement
Albany Molecular Research, Inc. announced a new drug discovery research agreement with Eli Lilly and Company, continuing an ongoing relationship between the two companies that began in 1998. Under the terms of the agreement, AMRI will provide fee-for-service chemistry research on projects in strategic therapeutic areas identified by Lilly. Though specific financial details were not disclosed, the contract includes fee-for-service provisions and is a continuation of a recently expired agreement.
"We believe that Lilly's decision to continue this significant relationship with AMRI reflects the value that AMRI's scientists have been able to bring to the collaboration," said AMRI Chairman, President and Chief Executive Officer Thomas E. D'Ambra, Ph.D.
Other news from the department business & finance

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Borealis appoints Eberhard Dreher as third Chief Scientist
Enerkem raises C$50 million in latest financing round
Microscopy Today Innovation Award for novel X-ray lenses - High numerical aperture and sharp focus enable record resolution microscopy

Nanoplastics can disrupt human liver, lung cells’ processes in lab experiments - What happens when people unknowingly eat, drink or inhale nearly invisible pieces of plastic?
Borouge signs major contracts valued at US$ 2.6 billion to advance its strategic Borouge 3 expansion
